Discover how next-generation sequencing and patient-derived xenografts are transforming treatment for aggressive-variant prostate cancer through personalized medicine approaches.
Discover how the MIG6 protein acts as a molecular double agent in prostate cancer cells, serving as a natural brake against cancer growth signals.
Discover how integrated genomic analysis reveals critical regions in the prostate tumor microenvironment that predict cancer aggressiveness and guide personalized treatment.
Discover how CRISPR screening technology is identifying novel epigenetic co-factors of oncogenic AR-activity in prostate cancer treatment resistance.
Examining disparities in next-generation sequencing testing access between Medicare Advantage and Traditional Medicare for metastatic prostate cancer patients.